BIOGNOSYS
Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced they will be presenting major scientific and technological advances on their proprietary proteomics research services, software, and kits at the American Society for Mass Spectrometry (ASMS) Annual Conference from October 31st to November 4th in Philadelphia (USA).
Biognosys will present a record number of 3 oral presentations, 10 scientific posters, 2 poster collaborations, 1 workshop panel, and 2 Spectronaut™ breakfast seminars . In addition, their team of scientific experts will be present at booth #224 to answer questions and demo software. Further demo sessions will be offered at the Bruker Daltonics booth #719.
Collectively, this presence demonstrates Biognosys’ significant contributions to transforming life science and clinical research with next-generation proteomics, particularly in the areas of plasma proteomics, immunopeptidomics, and proteomics data analysis.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys:
“Our major contribution to the ASMS scientific program is a testimony of Biognosys’ relentless commitment to innovation in mass spectrometry-based proteomics and progress in life science and clinical research.”
Discovering biomarkers in cancer with next-generation plasma proteomics
The plasma proteome is an underexplored source of insights on the health state of an individual. Biognosys will present results from a deep human plasma profiling study on a cohort of 180 lung, breast, colorectal, pancreatic, and prostate cancer patients, using an early version of their next-generation Plasma Biomarker Discovery workflow, launching in November. The workflow is optimized for use on Thermo Fisher Scientific Exploris 480 and FAIMS Pro instruments. Out of the entire plasma proteome, they quantified over 2,700 proteins and identified a protein panel with a significant positive predictive value for individual cancer stages.
Andreas Huhmer, Senior Director Life Sciences Research OMICS Marketing
at Thermo Fisher Scientific:
“Biognosys has a proven track record for maximizing all innovative features of the Thermo Scientific™ Orbitrap™ mass spectrometers in state-of-the-art proteome analysis. Their new Plasma Biomarker Discovery workflow is a good example of this. The unprecedented depth and quantitative precision they can achieve, coupled with the inherently unbiased nature of mass spectrometry-based analysis, has the potential to take plasma biomarker discovery to the next level.”
Gaining insights on the immune system to support personalized drug development
Immunopeptides play an essential role in the immune system and can be analyzed to support the development of personalized treatments. Mass spectrometry is currently the only technology that can reliably measure and identify immunopeptide profiles of biological samples on a large scale. Biognosys will present their immunopeptidomics workflow, optimized to provide deep and comprehensive biological insights on the immune system in large-scale clinical studies.
Turning data to insights with Spectronaut™, SpectroMine™, and SpectroDive™
Biognosys provides leading software products for proteomics data analysis. In a series of talks, their team will detail how they leverage the latest developments in Machine Learning and Deep Learning to allow deeper insights into the proteome. Biognosys is also excited to host two breakfast seminars with three guest speakers sharing their latest results from using Spectronaut in their research projects. In addition, a sneak-peak into the next planned release will be disclosed.
Gary Kruppa, Vice President, Proteomics at Bruker Daltonics:
“Biognosys’ software tools are among the top solutions for the analysis of proteomics data generated with Bruker instruments. Particularly the latest Spectronaut version yields spectacular performance improvements for dia-PASEF data. We invite all Bruker users to experience Spectronaut’s capabilities and enjoy the exceptional support Biognosys provides.”
Visit biognosys.com/asms2021 for a complete overview of Biognosys’ presence at ASMS.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005530/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
26th UN Tourism General Assembly kicks off in Riyadh7.11.2025 22:13:00 CET | Press release
UN Tourism marks 50 years of global cooperation as leaders from across the industry gather to shape the future of tourism. His Excellency Ahmed Al Khateeb, Minister of Tourism – “The Kingdom will play an integral part in ensuring one of the world’s most powerful generators of jobs and GDP grows in harmony with the Sustainable Development Goals.” UN Tourism Secretary-General ZurabPololikashvili – “The UN Tourism General Assembly brings together tourism leaders from across the world to set the agenda and build a more innovative and inclusive sector. From Riyadh, we will set the agenda for tourism for the years ahead.” The 26th session of the UN Tourism General Assembly opened today in Riyadh, marking a historic first for the Gulf Cooperation Council (GCC) region and the largest Assembly since UN Tourism was founded 50 years ago. Around 160 delegations from member states including ministers, senior officials, and leaders from across industry and civil society are coming together to celebr
Xsolla Partners With Deloitte Turkiye and Lorien Accelerator as Category Sponsor for Gaming Awards at Fast 50 Türkiye 2025 Program7.11.2025 19:11:00 CET | Press release
Celebrating Turkey’s Gaming Industry with High-Impact Sponsorship and Industry Panel Xsolla, a leading global video game commerce company that helps developers launch, grow, and monetize their games, is proud to announce its sponsorship of the Gaming Awards segment at the Deloitte Technology Fast 50 Türkiye 2025 Program, organized in collaboration with Lorien Accelerator. The event will take place on December 10, 2025, and will recognize Turkey’s top high-growth companies across various industries, with a special focus on the dynamic gaming sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107671030/en/ Graphic: Xsolla As the Gaming Awards category sponsor, Xsolla will receive significant brand exposure through prominent logo placements across all event materials, including digital platforms, official event signage, and other promotional materials. In addition to this visibility, Xsolla’s participation includes an ex
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 17:00:00 CET | Press release
− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose1− Rapid Reductions in Proteinuria and Serum Gd-IgA1 Levels Were Sustained Through Week 961− No Serious Adverse Events or Opportunistic Infections Were Observed Through Week 961− Takeda Initiated Pivotal Phase 3 Clinical Trials Evaluating Mezagitamab in Primary IgA Nephropathy and Immune Thrombocytopenia with Patient Enrollment Ongoing Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society o
Oremus Corporate Services Expands into Europe with Launch in Finland7.11.2025 16:23:00 CET | Press release
CEO, Lalit Ananth Chawla, to Attend Slush 2025 in Helsinki Oremus Corporate Services Private Limited, a multinational Finance and Accounting Advisory firm having its offices in the USA, India and the UK, has announced the extension of its services to Finland, marking the company’s foray into the European market. With over two decades of expertise in accounting, payroll, tax compliance, and advisory services, Oremus has earned trust as a technology-driven finance partner serving clients across geographies. Oremus is an ISAE 3402, ISO 27001, GDPR & DPDP Compliant Company, adhering to International Quality and Security Standards. “Finland isn’t just a new market for us — it’s the gateway to meaningful, growth-driven partnerships across Europe”. said Lalit Ananth Chawla, CEO of Oremus. Having established a strong reputation for delivering reliable Accounting and Advisory solutions to scale-ups and growing businesses, we seek to collaborate with like-minded firms and investors to build a tr
Experian Named a Leader in IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment7.11.2025 15:00:00 CET | Press release
Advanced fraud prevention, multi-layered verification and innovative data-driven security solutions are core to Experian’s Ascend Platform™ Experian today announced it has been named a leader in the IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment (doc # US52985325, September 2025). The report evaluates vendors on the depth and breadth of their identity verification capabilities and on how effectively they align with current and future customer needs. The IDC MarketScape methodology for this assessment involved two key measures of success: capabilities that reflect Experian’s current menu of services and how well aligned they are to its customer needs as well as strategies that indicate how well Experian’s future strategy aligns with what customers will require in three to five years. “This assessment offers a 360-degree view of our identity-verification solutions, and we’re very proud to be recognized as a leader,” said Keith Little, Presid
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom